0001209191-19-056047.txt : 20191112
0001209191-19-056047.hdr.sgml : 20191112
20191112164257
ACCESSION NUMBER: 0001209191-19-056047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191112
FILED AS OF DATE: 20191112
DATE AS OF CHANGE: 20191112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZACCARDELLI DAVID
CENTRAL INDEX KEY: 0001627642
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38135
FILM NUMBER: 191210274
MAIL ADDRESS:
STREET 1: 300 TRI STATE INTERNATIONAL
STREET 2: SUITE 272
CITY: LINCOLNSHIRE
STATE: IL
ZIP: 60069
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001685071
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813858961
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
BUSINESS PHONE: 919-806-4487
MAIL ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
FORMER COMPANY:
FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20160919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-12
1
0001685071
Dova Pharmaceuticals Inc.
DOVA
0001627642
ZACCARDELLI DAVID
C/O DOVA PHARMACEUTICALS, INC.
240 LEIGH FARM ROAD, SUITE 245
DURHAM
NC
27707
1
1
0
0
President & CEO
Common Stock
2019-11-12
4
D
0
76647
D
0
D
Employee Stock Option (Right to Buy)
6.07
2019-11-12
4
D
0
1000000
D
2018-12-18
Common Stock
1000000
0
D
Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-11-12